IRON TECH(SH:688329)2022-04-29 16:00Financial Performance - The company's operating revenue for 2021 was approximately RMB 389.32 million, representing a year-on-year increase of 25.60% compared to RMB 309.98 million in 2020[24]. - The net profit attributable to shareholders of the listed company increased by 33.40% year-on-year to approximately RMB 95.59 million, up from RMB 71.66 million in 2020[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 42.20% year-on-year to approximately RMB 88.91 million[24]. - The total assets of the company increased by 43.18% year-on-year to approximately RMB 1.14 billion, up from RMB 795.96 million in 2020[25]. - The net assets attributable to shareholders of the listed company increased by 76.31% year-on-year to approximately RMB 803.13 million[25]. - The basic earnings per share for 2021 was RMB 1.32, a 6.45% increase from RMB 1.24 in 2020[26]. - The company's gross profit margin for the main business was 60.16%, which increased by 0.73 percentage points year-on-year[113]. - The revenue from the automation pharmacy segment was CNY 279,202,574.01, with a gross profit margin of 64.35%, showing a decrease of 1.25 percentage points[113]. - The company achieved a total R&D investment of ¥39,611,447.29 in the current year, representing a 22.86% increase compared to ¥32,242,358.85 in the previous year[83]. Cash Flow and Dividends - The company plans to distribute a cash dividend of 5 yuan (including tax) for every 10 shares, totaling 38.6 million yuan, which represents 40.38% of the net profit attributable to shareholders for 2021[5]. - The net cash flow from operating activities decreased by 66.09% year-on-year to approximately RMB 39.75 million, primarily due to an increase in advance payments for orders[27]. - The company’s cash flow must meet operational and developmental needs to implement cash dividends[194]. - The company will conduct profit distribution at least once a year, subject to meeting specific conditions such as profitability and positive retained earnings[194]. - The company has established a stable profit distribution policy, ensuring reasonable returns for investors while maintaining normal operations and long-term development[193]. Research and Development - The research and development expenditure accounted for 10.17% of operating revenue, slightly down from 10.40% in 2020[26]. - The company applied for 830 patents and obtained 372 patents by the end of 2021, enhancing its core competitiveness through innovation[39]. - The company has developed 8 core key technologies, with a total of 161 authorized invention patents, enhancing its capabilities in smart medical management[77]. - The company is currently testing an AI-based empty bottle recognition system for anesthesia drugs, which is in the trial production stage and aims to enhance safety in operating rooms[87]. - The company is focusing on expanding its market presence through innovative products and technologies, aiming for significant growth in the healthcare sector[85]. Market and Industry Outlook - The medical equipment industry is expected to accelerate growth starting in 2022, driven by the ongoing development of new medical infrastructure since 2020[41]. - The company is positioned to benefit from increasing hospital numbers and rising government healthcare spending, which are driving industry demand[150]. - The healthcare infrastructure development is expected to accelerate growth in the medical equipment industry starting from 2022, providing opportunities for the company[151]. - The company plans to expand its market presence by entering new regions and increasing its product offerings in 2022[164]. - Future guidance suggests a revenue growth target of 10-15% for the upcoming fiscal year[164]. Corporate Governance - The board consists of 9 directors, including 3 independent directors, ensuring compliance with governance regulations[155]. - The supervisory board has 3 members, including 1 employee representative, to ensure independent oversight of company operations[156]. - The company is committed to maintaining high corporate governance standards to protect shareholder interests[155]. - The company has not faced any penalties from securities regulatory authorities in the past three years[175]. - The company’s profit distribution principles align with regulatory requirements, ensuring protection of shareholder interests, particularly for minority investors[192]. Strategic Initiatives - The company aims to optimize its industrial structure and deepen its business development in the intelligent material management sector, targeting the smart medical project business segment[41]. - The company plans to enhance collaboration between upstream and downstream industries to improve operational efficiency and product development[151]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[164]. - The company plans to implement new marketing strategies aimed at increasing brand awareness and customer engagement, with a budget allocation of 50 million RMB[171]. - The company aims to improve operational efficiency, targeting a 15% reduction in costs through process optimization initiatives[171].